January 26, 2021 – OraSure Technologies, Inc. announced that Chronomics Limited has selected the OMNIgene·ORAL (OME-505) saliva collection device as a component of its SARS CoV-2 PCR test.
Chronomics Limited will supply its test for the United Kingdom’s “Test to Release for International Travel” program. The OMNIgene·ORAL device is a product of OraSure’s DNA Genotek subsidiary.
The “Test to Release for International Travel” program enables travelers to England to purchase a COVID-19 test privately from providers including Chronomics. Travelers who receive a negative test result can reduce their self-isolation period. The project is part of the UK’s plan to use Covid-19 testing to reduce the spread of the virus.
The OMNIgene·ORAL (OME-505) collection device has Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) and is CE marked for use in the European Union.